A Phase I/II Trial of Topotecan With VX970, an ATR Kinase Inhibitor in Small Cell Cancers
Phase of Trial: Phase I/II
Latest Information Update: 11 Dec 2017
At a glance
- Drugs M 6620 (Primary) ; Topotecan
- Indications Cervical cancer; Neuroendocrine tumours; Non-small cell lung cancer; Ovarian cancer; Small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Nov 2017 Planned End Date changed from 30 Oct 2020 to 30 Oct 2025.
- 12 Jul 2017 Planned number of patients changed from 55 to 70.
- 04 May 2017 Planned primary completion date changed from 31 May 2018 to 31 May 2019.